What Myovant Sciences Ltd.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 0 | 0 |
| Total trades | 0 | 0 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 0 |
| Disposed | 0 | 0 |
| Net activity | +0 | +0 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Sumitomo Chemical Co., Ltd. | 10% owner | Mar 10 | Open-market buy · P | +51,599,200 | $27.00 | +$1.39B | 45,798,176 |
| Potter Myrtle S | Director | Mar 10 | Disposition to Issuer · D | −3,673 | — | — | 0 |
| Marek David C | Principal Executive Officer | Mar 10 | Disposition to Issuer · D | −321,924 | — | — | 0 |
| Marek David C | Principal Executive Officer | Mar 10 | Disposition to Issuer · D | −95,675 | — | — | 321,924 |
| Mehra Uneek | Principal Financial Officer | Mar 10 | Disposition to Issuer · D | −181,972 | — | — | 0 |
| Mehra Uneek | Principal Financial Officer | Mar 10 | Disposition to Issuer · D | −20,724 | — | — | 181,972 |
| Lang Matthew | General Counsel & Corp. Secy. | Mar 10 | Disposition to Issuer · D | −241,158 | — | — | 0 |
| Lang Matthew | General Counsel & Corp. Secy. | Mar 10 | Disposition to Issuer · D | −113,145 | — | — | 241,158 |
| Valente Nancy | Director | Mar 10 | Disposition to Issuer · D | −3,673 | — | — | 0 |
| Guinan Mark | Director | Mar 10 | Disposition to Issuer · D | −3,673 | — | — | 0 |
| Curran Terrie | Director | Mar 10 | Disposition to Issuer · D | −3,673 | — | — | 0 |
| Gulfo Adele M. | Director | Mar 10 | Disposition to Issuer · D | −3,673 | — | — | 0 |
| Arjona Ferreira Juan Camilo | Chief Medical Officer | Mar 10 | Disposition to Issuer · D | −160,082 | — | — | 0 |
| Arjona Ferreira Juan Camilo | Chief Medical Officer | Mar 10 | Disposition to Issuer · D | −86,602 | — | — | 160,082 |
| Merendino Lauren | Chief Commercial Officer | Mar 10 | Disposition to Issuer · D | −147,747 | — | — | 0 |
| Merendino Lauren | Chief Commercial Officer | Mar 10 | Disposition to Issuer · D | −21,791 | — | — | 147,747 |
| Sumitomo Chemical Co., Ltd. | 10% owner | Mar 03 | Other Transaction · J | −4,243,005 | — | — | 45,798,176 |
| Merendino Lauren | Chief Commercial Officer | Jan 18 | Sale for tax withholding · S | −2,008 | $26.89 | −$54K | 169,538 |
| Arjona Ferreira Juan Camilo | Chief Medical Officer | Jan 18 | Sale for tax withholding · S | −1,109 | $26.89 | −$29.8K | 246,684 |
| Marek David C | Principal Executive Officer | Jan 18 | Sale for tax withholding · S | −8,037 | $26.89 | −$216K | 417,599 |
Loading...